Sponsor

Bausch & Lomb Incorporated

Clinical research sponsor

Published trials20
Recruiting shown1
Roles2
SourceClinicalTrials.gov

Clinical trials

20 shown
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902 · lead sponsor · 2025-10-24
COMPLETED
A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionNCT04140279 · lead sponsor · 2022-05-13
WITHDRAWN
Safety and IOP-Lowering Effects of WB007NCT04149899 · lead sponsor · 2019-11-14
COMPLETED
Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT03896633 · lead sponsor · 2018-02-28
COMPLETED
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHTNCT01895972 · lead sponsor · 2013-07-05
COMPLETED
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749904 · lead sponsor · 2013-01-31
COMPLETED
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749930 · lead sponsor · 2013-01-01
COMPLETED
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01707381 · lead sponsor · 2012-11-01
COMPLETED
Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT01722604 · lead sponsor · 2012-01-01
COMPLETED
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionNCT01223378 · lead sponsor · 2010-12-13
COMPLETED
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.NCT00595101 · lead sponsor · 2007-12-01
COMPLETED
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for GlaucomaNCT00441883 · lead sponsor · 2007-03-01
COMPLETED
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous DetachmentNCT00198471 · lead sponsor · 2005-07-01
COMPLETED
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhageNCT00198497 · lead sponsor · 1999-06-01
COMPLETED
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhageNCT00198510 · lead sponsor · 1998-11-01
COMPLETED
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical MedicationsNCT04354545 · collaborator · 2021-04-01
RECRUITING
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour PeriodNCT07090044 · collaborator · 2021-08-20
COMPLETED
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual AcuityNCT03931317 · collaborator · 2018-12-03
COMPLETED
Evaluation of Ocular Surface Inflammatory Mediators Effected by LotemaxNCT02322528 · collaborator · 2014-04-01
COMPLETED
Clinical Trial on Alpha Lipoic Acid in Diabetic Macular EdemaNCT01208948 · collaborator · 2000-07-01
COMPLETED

Sponsor roles

lead sponsor15
collaborator5

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.